A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB

Authors
Category Primary study
ConferenceEHA2023 Hybrid Congress
Year 2023
This article has no abstract
Epistemonikos ID: 10759909b73587cd8607d871d3a257d766e923bd
First added on: Apr 25, 2026